Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

We are recently faced with a progressive evolution of the therapeutic paradigm for radioiodine refractory differentiated thyroid cancer (RAI-R DTC), since the advent of tissue agnostic inhibitors. Thus, tumor genotype assessment is always more relevant and is playing a crucial role into clinical pra...

Full description

Bibliographic Details
Main Authors: Margherita Nannini, Andrea Repaci, Gianluca Ricco, Manuela Ianni, Arber Golemi, Vincenzo Maiolo, Marco Ferrari, Filippo Natali, Elisa Lodi Rizzini, Fabio Monari, Erica Solaroli, Antonio De Leo, Thais Maloberti, Maria A. Pantaleo, Dario De Biase, Giovanni Tallini
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
differentiated thyroid cancer
papillary thyroid carcinoma
RET
RET-rearrangement
RET-inhibitor
pralsetinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1042525/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1042525/full

Similar Items